Clinical Trial Update: Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects. [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated the safety and efficacy of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• Promacta (eltrombopag)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Aplastic Anemia | Phase 2 | Status: COMPLETED | Results posted: 2025-02-03